TG THERAPEUTICS (TGTX) Company Report

TG Therapeutics is targeting $585 million in Briumvi revenues for the current year (2025) and expects a significantly larger number for next year (2026), though specific guidance has not yet been provided.
The company anticipates data from its consolidated dosing study in the middle to early second half of 2026 and aims to complete enrollment for its sub-Q program in the first half of 2026, with data expected toward the end of 2026.
Briumvi currently captures approximately one out of three new IV anti-CD20 patients, representing about a 20% share within the CD20 class and a 10% share among all MS new starts. TG Therapeutics plans a strategic sales force expansion, likely in the 10-20% range, to be completed by mid-2026.
The proprietary sub-Q Briumvi formulation has provisional patents filed, which, if issued, could provide patent protection until 2045.

8 days ago

Transcript

TG Therapeutics Updates on Briumvi Performance and Pipeline Progress

TGTX

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

TG Therapeutics is targeting $585 million in Briumvi revenues for 2025.
The Briumvi consolidated dosing study expects data in the middle to early second half of 2026, and the sub-Q program anticipates completing enrollment in the first half of 2026 with data by the end of 2026.
The proprietary sub-Q Briumvi formulation has provisional patents filed, potentially providing patent protection until 2045.
The company plans a strategic sales force expansion focusing on specific areas of weakness to optimize prescriber breadth and depth.

8 days ago

Transcript

TG Therapeutics Discusses Briumvi Market Performance, SubQ Development, and 2026 Growth Initiatives

TGTX

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

Briumvi IV is gaining market share, with physicians moving it into the first IV slot due to data, convenience, and generous patient support programs. The company notes a significant proportion of patients switching from other CD20 therapies and other non-CD20 therapies.
The Enhanced trial for Briumvi, which combines initial doses, has seen impressive enrollment and aims for non-inferiority in area under the curve, potentially speeding up patient initiation by simplifying scheduling.
TG Therapeutics is not observing a significant market impact from Ocrevus SubQ and anticipates that BTK inhibitors will primarily compete in the oral product category rather than against CD20 infusions, citing compliance issues and efficacy preferences.
For Q4 2025, the company expects better growth than Q3 and is confident in meeting or exceeding its stated guidance.
The pivotal trial for SubQ Briumvi is projected to complete enrollment in H1 2026, with data expected in late 2026 or early 2027, targeting filing in H2 2027 and approval in H2 2028. This product is considered a significant opportunity, potentially expanding the total addressable market by 35%-40%.

Nov 12, 2025, 3:00 PM

Transcript

TG Therapeutics Discusses Briumvi Performance and Future Growth Initiatives

TGTX

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

Briumvi has achieved a strong position as the number one IV treatment in some academic centers, driven by data, patient convenience, and generous patient support programs, with a stable mix of new and crossover patients.
TG Therapeutics anticipates the enhanced trial (one-dose switch) for Briumvi will simplify scheduling and accelerate patient onboarding, receiving positive clinician feedback.
Management is confident in meeting or exceeding Q4 guidance for Briumvi and plans to accelerate 2026 growth by expanding its direct-to-consumer (DTC) campaign and strategically growing its field team.
The subcutaneous (subQ) Briumvi trial aims for enrollment completion in H1 2026, data in late 2026/early 2027, and approval in H2 2028, potentially doubling the total addressable market by entering the self-injectable segment.
The company observes limited market impact from Ocrevus SubQ and expects BTK inhibitors to compete mainly with oral products, not CD20s, citing skepticism about their efficacy.

Nov 12, 2025, 3:00 PM

Transcript

TG Therapeutics Discusses Briumvi Market Dynamics and Future Growth Plans

TGTX

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

Briumvi is increasingly adopted as the first IV slot by physicians, driven by strong data, convenience, and its leading patient support programs. A significant portion of patients are crossovers from other therapies, including other CD20s.
TG Therapeutics anticipates stronger growth in Q4 compared to Q3 and is confident in meeting or exceeding its guidance. For 2026, the company plans to expand its direct-to-consumer (DTC) campaign and strategically add to its field team to accelerate growth.
The enhanced trial for Briumvi, aiming for a one-dose switch, is expected to simplify patient initiation. Enrollment for the subcutaneous (SUB-Q) Briumvi trial is projected to complete in H1 2026, with data in late 2026 or early 2027, and targeted approval in H2 2028; this SUB-Q version is expected to significantly expand the total addressable market.
The company observes minimal market impact from Ocrevus SUB-Q. Regarding BTK inhibitors, the CEO believes they will primarily compete with oral products rather than CD20s, citing concerns about efficacy in PPMS and a history of failed RMS studies.

Nov 12, 2025, 3:00 PM

Transcript

TG Therapeutics Reports Strong Q3 2025 Results and Raises Full-Year BRIUMVI Revenue Guidance

TGTX

Earnings

Guidance Update

Share Buyback

TG Therapeutics reported total revenue of $161.7 million for Q3 2025, with US BRIUMVI net sales of $152.9 million.
The company achieved GAAP net income of $390.9 million ($2.43 per diluted share) in Q3 2025, which included a $365 million non-recurring income tax benefit, marking its sixth consecutive quarter of profitability.
TG Therapeutics raised its full-year 2025 US BRIUMVI net revenue guidance to approximately $585 million.
The initial $100 million share repurchase program was completed, and another $100 million program was authorized.
Advancements in the BRIUMVI pipeline include completed enrollment for the ENHANCE study (data by mid-2026) and the subcutaneous BRIUMVI study (enrollment completion H1 2026), which could nearly double BRIUMVI's total addressable market.

Nov 3, 2025, 1:30 PM

Transcript

TG Therapeutics Reports Strong Q3 2025 Results, Raises BRIUMVI Revenue Guidance, and Advances Pipeline

TGTX

Earnings

Guidance Update

Share Buyback

TG Therapeutics reported Q3 2025 total revenue of $161.7 million, a 93% increase compared to Q3 2024, driven by U.S. BRIUMVI net sales of $152.9 million.
The company achieved GAAP net income of $390.9 million, or $2.43 per diluted share, which included a non-recurring income tax benefit of approximately $365 million.
TG Therapeutics raised its full-year 2025 U.S. BRIUMVI net revenue guidance to approximately $585 million.
The company completed a $100 million share repurchase program and the board authorized an additional $100 million program.
Key pipeline advancements include completed enrollment for the ENHANCE study with data expected by mid-2026, and the subcutaneous ublituximab study on track for top-line data in late 2026 or early 2027, which could nearly double BRIUMVI's addressable market.

Nov 3, 2025, 1:30 PM

Transcript

TG Therapeutics Reports Strong Q3 2025 Results and Raises Full-Year BRIUMVI Revenue Guidance

TGTX

Earnings

Guidance Update

New Projects/Investments

TG Therapeutics reported strong Q3 2025 financial results, with total revenue reaching $161.7 million, a 93% increase compared to Q3 2024, and GAAP net income of $390.9 million, or $2.43 per diluted share, which includes a $365 million non-recurring income tax benefit. This marks the sixth consecutive quarter of profitability.
The company raised its full-year 2025 US BRIUMVI net revenue guidance to approximately $585 million, driven by strong demand and execution, with Q3 2025 US BRIUMVI net sales totaling $152.9 million.
Significant progress was made in the BRIUMVI pipeline, with the ENHANCE study (simplified IV dosing) completing enrollment for potential launch in 2027, and the Phase 3 subcutaneous BRIUMVI study on track for top-line data in late 2026 or early 2027 and potential launch in 2028, which could nearly double the total addressable market.
TG Therapeutics completed its initial $100 million share repurchase program, buying back 3.5 million shares at an average price of about $28.50, and the board authorized an additional $100 million program.

Nov 3, 2025, 1:30 PM

Transcript

TG Therapeutics Reports Strong Q3 2025 Financial Results, Raises Revenue Guidance, and Authorizes New Share Repurchase Program

TGTX

Earnings

Guidance Update

Share Buyback

Q3 2025 total revenue reached $161.7 million, with BRIUMVI U.S. net revenue at $152.9 million, marking an 84% growth over the same period in 2024.
The company raised its full-year 2025 global revenue target to $600 million and its full-year BRIUMVI U.S. net revenue target to approximately $585 million.
Net income for Q3 2025 was $390.9 million, or $2.43 per diluted share, significantly boosted by a $365.0 million non-recurring income tax benefit.
TG Therapeutics completed its initial $100 million share repurchase program and authorized an additional $100 million program.

Nov 3, 2025, 12:34 PM

8-K

TG Therapeutics Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance

TGTX

Earnings

Guidance Update

Share Buyback

TG Therapeutics reported total revenue of $161.7 million for the third quarter of 2025, with BRIUMVI U.S. net revenue reaching $152.9 million.
The company raised its full-year 2025 global revenue target to $600 million and its full-year BRIUMVI U.S. net revenue target to approximately $585 million.
Net income for Q3 2025 was $390.9 million, which included a $365.0 million non-recurring income tax benefit.
TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million program.